NCT01908972

The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 9 Months
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.

Detailed description

* Randomized (A group : propranolol, B group : prednisolone) * A group : 3 days admission and medication for 16 weeks * B group : medication for 16 weeks without admission * Hemangioma volume comparison by using MRI * other measurement and drug adverse reaction monitoring

Conditions

• Hemangioma

Interventions

Type	Name	Description
DRUG	Prednisolone	2mg/kg/day for 16weeks
DRUG	Propranolol	2mg/kg/day for 16weeks

Timeline

• Start date: 2013-06-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2013-07-26
• Last updated: 2018-12-19
• Results posted: 2018-10-26

Locations

1 site across 1 country: South Korea